Dana-Farber is committed to ensuring the veracity of research conducted under its oversight and follows strict policies and procedures to ensure its research meets the highest ethical standards. Following is an overview of relevant board memberships, outside support, and significant advisory roles as reported by several physicians and researchers featured in the 2020 issue of Dana-Farber's Paths of Progress magazine.

• Shom Goel, MD, PhD, has served as a consultant for Eli Lilly, Novartis, and G1 Therapeutics. His lab has received research funding from Eli Lilly and G1 Therapeutics, and has conducted clinical trial research funded by Eli Lilly and Novartis.
• Keith L. Ligon, MD, PhD, is a co-founder and scientific advisory board member of Travera LLC. He is a scientific advisory board member of Integragen (France), a consultant for Bristol Myers Squibb, Rarecyte, and BroadBranch Advisors. The Ligon Lab receives or has received research funding and licensing fees through Dana-Farber from BMS, Lilly, Amgen, Tragara, and Novartis. He holds, with Dana-Farber, a patent on cancer diagnostics.
• Geoffrey Oxnard, MD, has received consulting fees or honoraria from Foundation Medicine, Guardant, Inivata, Sysmex, GRAIL, and Illumina.
• Deborah Schrag, MD, MPH, is an editor of the Journal of the American Medical Association and receives compensation for that work.
• Jean Zhao, PhD, is a co-founder and director of Crimson BioPharma Inc. and Geode Therapeutics Inc. The Zhao lab receives or has received research funding from Novartis, Lilly, Puma, Sanofi and Daiichi.